Related Experiment Video
Updated: Feb 9, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms
1Breast Cancer Research Program, Weill Medical College of Cornell University, 425 E. 61st, 8th Floor, New York, NY 10065, USA. ltv2001@med.cornell.edu
Abstract:
Tumor resistance to chemotherapeutic agents ultimately leads to treatment failure in the majority of cancer patients. The identification of new agents that are less susceptible to mechanisms of tumor resistance could, therefore, bring significant clinical benefits to patients with advanced cancer. One new drug class of great interest in this respect is the epothilones and their analogues, which are microtubule inhibitors with low susceptibility to several mechanisms of drug resistance. Ixabepilone is an analogue of natural epothilone B with activity against a wide range of tumor types, including drug-resistant tumors. This is consistent with the preclinical activity of ixabepilone against human cancer cell lines resistant to taxanes and other agents. Taxane resistance in these cells may be acquired or primary and results from several mechanisms, such as overexpression of multidrug-resistance proteins and the betaIII-tubulin isoform. Ixabepilone has demonstrated efficacy as monotherapy or in combination with capecitabine in anthracycline- and taxane-pretreated/resistant metastatic breast cancer (MBC), and has recently been approved for use in resistant/refractory MBC. Other epothilones, such as patupilone, KOS-1584, and ZK-EPO, are also being evaluated in drug-resistant cancers. Ixabepilone represents a new treatment option for MBC patients with cancers resistant to available chemotherapeutic agents.
Insights
Ixabepilone, a novel epothilone, shows promise against drug-resistant cancers, particularly metastatic breast cancer (MBC). This microtubule inhibitor offers a new treatment option for patients resistant to traditional chemotherapy agents.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Tumor resistance to chemotherapy is a major cause of treatment failure in advanced cancers.
- Developing novel agents less susceptible to resistance mechanisms is crucial for improving patient outcomes.
- Epothilones, a class of microtubule inhibitors, exhibit low susceptibility to common drug resistance mechanisms.
Purpose of the Study:
- To evaluate the efficacy of ixabepilone, an epothilone analogue, in treating drug-resistant cancers.
- To assess ixabepilone's activity against various cancer cell lines, including those with acquired or primary resistance to taxanes and other agents.
- To highlight ixabepilone as a potential new therapeutic option for metastatic breast cancer (MBC) patients with resistant tumors.
Main Methods:
- Preclinical evaluation of ixabepilone against human cancer cell lines resistant to taxanes and other chemotherapeutic agents.
- Clinical assessment of ixabepilone as monotherapy and in combination with capecitabine in anthracycline- and taxane-pretreated/resistant metastatic breast cancer (MBC).
- Review of ongoing clinical trials for other epothilones (patupilone, KOS-1584, ZK-EPO) in drug-resistant cancers.
Main Results:
- Ixabepilone demonstrated preclinical activity against cancer cell lines exhibiting resistance to taxanes and other agents, attributed to mechanisms like multidrug-resistance protein overexpression and betaIII-tubulin isoform.
- Ixabepilone showed efficacy in clinical trials for anthracycline- and taxane-pretreated/resistant metastatic breast cancer (MBC), both as a single agent and in combination therapy.
- Ixabepilone has received approval for use in resistant/refractory MBC, indicating its clinical benefit.
Conclusions:
- Ixabepilone is an effective treatment option for patients with metastatic breast cancer (MBC) that is resistant to existing chemotherapeutic agents.
- The low susceptibility of ixabepilone to common drug resistance mechanisms makes it a valuable addition to the oncology armamentarium.
- Ongoing research into other epothilones suggests a broader potential for this drug class in overcoming tumor resistance.
Related Concept Videos
Magnetic Susceptibility and Permeability
When diamagnetic materials are placed under an external magnetic field, the moments opposite to the field are induced. Hence, the susceptibility for diamagnets has a minimal negative value of 10-5–10-6. Since...
Resistivity
Resistance
Susceptibility, Permittivity and Dielectric Constant
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Multiple Allele Traits

